RB1 and cancer: Targeting Cyclin-dependent Kinase 4 (CDK4) and Cyclin-dependent Kinase 6 (CDK6) in ER+ breast cancer is useful because these cancers often have the cyclin D1–CDK4/6–Rb pathway activated.